URGN — UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $109.8 million for the year ended December 31, 2025, up 21% from $90.4 million in 2024.
• Zysturi Revenue: $15.8 million for 2025, reflecting early launch dynamics.
• Jelmyto Revenue: $94 million for 2025, indicating continued underlying demand growth.
• Net Loss: $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024.
• Cash Position: $120.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Debt Refinancing: Entered into a new $250 million loan agreement, enhancing financial flexibility and reducing interest costs.

2. Strategic Updates and Business Highlights

• Zysturi Launch: The company is focused on the commercial launch of Zysturi for recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer. The permanent J code effective January 1, 2026, is expected to facilitate broader adoption.
• Pipeline Development: UGN-103 is on track for NDA submission in 2026, with potential FDA approval in 2027. UGN-104 is progressing through Phase 3 trials, with completion expected in 2026.
• Market Positioning: Zysturi is viewed as a significant advancement in bladder cancer treatment, offering a primary office-based therapy that extends treatment-free living.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Jelmyto net product revenue is expected to be between $97 million and $101 million, reflecting a growth rate of approximately 3% to 7% over 2025.
• Operating Expenses: Expected to be between $240 million and $250 million for 2026, driven by increased salesforce costs and life cycle management initiatives.

4. Bad News, Challenges, or Points of Concern

• Net Loss Increase: The net loss widened compared to the previous year, raising concerns about the path to profitability.
• Market Adoption: While early indicators for Zysturi are positive, the company has not provided formal sales guidance, indicating uncertainty in the launch trajectory.
• Competitive Landscape: The need to differentiate Zysturi and UGN-103 in a competitive market remains a challenge, particularly as they plan to transition from Zysturi to UGN-103.

5. Notable Q&A Insights

• Patient Enrollment and Prescriber Trends: Early indicators show that Zysturi is outperforming Jelmyto in terms of new patient starts and prescriber engagement. The company is optimistic about increasing repeat prescribers as confidence in reimbursement grows.
• Transition to UGN-103: The company plans to transition to UGN-103 after securing a permanent J code, with a cautious approach to avoid confusion among physicians and patients.
• Community vs. Academic Centers: There is a shift towards community practices adopting Zysturi, which is expected to contribute to growth as reimbursement processes normalize.
• Life Cycle Management: UGN-103 is being evaluated for use in adjuvant settings, with potential expansion opportunities in high-risk patient populations.

Overall, UroGen Pharma is navigating a critical phase with the launch of Zysturi while managing its financial health and preparing for future product developments. The company remains optimistic about its growth trajectory despite the challenges and uncertainties inherent in the pharmaceutical landscape.